Chemoinformaics analysis of 2,3,5,6-TETRAMETHYLPYRAZINE
| Molecular Weight | 136.198 | nRot | 0 |
| Heavy Atom Molecular Weight | 124.102 | nRig | 6 |
| Exact Molecular Weight | 136.1 | nRing | 1 |
| Solubility: LogS | -0.926 | nHRing | 1 |
| Solubility: LogP | 1.336 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 22 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 23.5615 |
| nHD | 0 | BPOL | 14.3185 |
| QED | 0.542 |
| Synth | 1.967 |
| Natural Product Likeliness | -0.451 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.007 |
| HIA | 0.011 |
| CACO-2 | -4.845 |
| MDCK | 0.0000242 |
| BBB | 0.975 |
| PPB | 0.603612 |
| VDSS | 1.392 |
| FU | 0.470934 |
| CYP1A2-inh | 0.386 |
| CYP1A2-sub | 0.905 |
| CYP2c19-inh | 0.018 |
| CYP2c19-sub | 0.497 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.087 |
| CYP2d6-inh | 0.151 |
| CYP2d6-sub | 0.846 |
| CYP3a4-inh | 0.013 |
| CYP3a4-sub | 0.558 |
| CL | 6.038 |
| T12 | 0.266 |
| hERG | 0.014 |
| Ames | 0.126 |
| ROA | 0.436 |
| SkinSen | 0.296 |
| Carcinogencity | 0.883 |
| EI | 0.991 |
| Respiratory | 0.56 |
| NR-Aromatase | 0.007 |
| Antiviral | No |
| Prediction | 0.90796 |